A Shot in the Arm to Fight Skin Cancer



    TORONTO, Jan. 15 /CNW/ -- Skin cancer patient Debra Gardocki receives an
injection from oncologist Dr. Sanjiv Agarwala as part of a study exploring a
new approach to treat advanced melanoma -- an often fatal form of cancer for
which there are limited effective treatment options. The study -- which is
taking place at up to 25 centers across the United States and Canada --
includes combining a therapeutic cancer vaccine along with more traditional
immune therapies.
    

    (Photo: http://www.newscom.com/cgi-bin/prnh/20090115/NY59314-a )
    (Photo: http://www.newscom.com/cgi-bin/prnh/20090115/NY59314-b )

    
    Therapeutic cancer vaccines are uniquely designed to stimulate the body's
own defenses -- the immune system -- to find and fight cancer cells. The
vaccine is designed to treat existing cancer rather than prevent it from
developing.  Sanofi Pasteur, the vaccines division of sanofi-aventis Group,
has invested more than five years of work to develop this vaccine regimen and
bring it to clinical trials.
    

    
    For more information about this trial, call 1-888-755-5209 or visit
www.cancervaccines.com. For the location of trial sites, go to
www.clinicaltrials.gov.
    

    About sanofi-aventis
    
    Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE:   SNY).
    

    
    Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided
more than 1.6 billion doses of vaccine in 2007, making it possible to immunize
more than 500 million people across the globe. A world leader in the vaccine
industry, sanofi pasteur offers the broadest range of vaccines protecting
against 20 infectious diseases. The company's heritage, to create vaccines
that protect life, dates back more than a century. Sanofi Pasteur is the
largest company entirely dedicated to vaccines. Every day, the company invests
more than EUR1 million in research and development. For more information,
please visit: www.sanofipasteur.com.
    


    

    
    U.S. Media Relations             Canadian Media Relations
    Len Lavenda                      Nancy Simpson
    T. +1-570-839-4446               T. +1-416-667-2955
    len.lavenda@sanofipasteur.com    nancy.simpson@sanofipasteur.com
    www.sanofipasteur.us             www.sanofipasteur.ca



    




For further information:

For further information: U.S. Media Relations, Len Lavenda,
+1-570-839-4446, len.lavenda@sanofipasteur.com, or Canadian Media Relations,
Nancy Simpson, +1-416-667-2955, nancy.simpson@sanofipasteur.com, both of
sanofi pasteur Web Site: http://www.sanofipasteur.com

Organization Profile

Sanofi Pasteur

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890